Predicted long‐term impact of <scp>COVID</scp>‐19 pandemic‐related care delays on cancer mortality in Canada

Malagón, Talía; Yong, Jean Hai Ein; Tope, Parker; Miller, Wilson H.; Franco, Eduardo L.

doi:10.1002/ijc.33884

Cited by 90 publications

(89 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on the findings of this study, the COVID-19 pandemic has negatively impacted cancer diagnoses in general and specialized practices in Germany. This disruption in cancer care may have major deleterious effects among patients with cancer, and these effects may include increased tumor dimensions (Vanni et al 2021 ) and higher rates of node invasion at diagnosis (Linck et al 2021 ) as well as higher short-term (Lai et al 2020 ) and long-term mortality (Alagoz et al 2021 ; Malagón et al 2021 ). Public health measures should be implemented in this country to mitigate the deleterious effects of this health crisis on the diagnosis of cancer.…”

Section: Discussionmentioning

confidence: 99%

Decrease in the number of patients diagnosed with cancer during the COVID-19 pandemic in Germany

Jacob

Kalder

Kostev³

2022

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose Little is known on how coronavirus disease 2019 (COVID-19) has impacted cancer diagnosis in Germany since the first lockdown in March 2020. Therefore, this retrospective study aimed to compare the number of patients newly diagnosed with cancer in general and specialized practices in Germany between April 2020–March 2021 and April 2019–March 2020. Methods Patients aged ≥ 18 years with at least 1 visit to 1 of 1403 general and specialized practices in Germany in April 2020–March 2021 ( n = 3,804,596) and April 2019–March 2020 ( n = 3,913,386) were included in this retrospective study. Specialized practices were composed of gynecology, dermatology and urology practices. Cancer diagnoses included all types of cancer documented using the International Classification of Diseases, 10th revision (ICD-10 codes: C00-C97). The number of patients newly diagnosed with cancer per practice was compared between April 2020–March 2021 and April 2019–March 2020 using Wilcoxon tests. Results There were 126,379 and 138,996 patients diagnosed with cancer in April 2020–March 2021 and April 2019–March 2020, respectively. The number of patients diagnosed with cancer decreased in all types of practice, and this decrease was significant in general practices (− 7.1%, p value = 0.038). In terms of cancer type, this decrease was particularly pronounced for skin cancers (− 12.8%, p value = 0.025). Conclusion The COVID-19 pandemic has been associated with a decrease in the number of patients newly diagnosed with cancer in general and specialized practices in Germany. Public health interventions are urgently warranted to mitigate the deleterious effects of this health crisis on cancer diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Decrease in the number of patients diagnosed with cancer during the COVID-19 pandemic in Germany

Jacob

Kalder

Kostev³

2022

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Each 4-week delay in cancer surgery, radiotherapy, or systemic therapy leads to a 6–8% increase in mortality, but there is evidence of significant heterogeneity in this association according to patient characteristics such as age, comorbidity, and geographic region [ 34 , 35 ]. Longer delays across multiple needed treatments are also associated with greater mortality [ 36 ]. Moreover, as we observed greater delays among individuals with Medicaid insurance, and others have found disparities in COVID-19-related changes in cancer screening among racial/ethnic minorities [ 37 ], the impact could be unevenly distributed and be more severe in vulnerable populations including patients with lower socioeconomic status.…”

Section: Discussionmentioning

confidence: 99%

Patient-Reported Experiences of Breast Cancer Screening, Diagnosis, and Treatment Delay, and Telemedicine Adoption during COVID-19

Du¹,

Carfang²,

Restrepo

et al. 2022

Current Oncology

View full text Add to dashboard Cite

Purpose: To evaluate and quantify potential sociodemographic disparities in breast cancer screening, diagnosis, and treatment due to the COVID-19 pandemic, and the use of telemedicine. Methods: We fielded a 52-item web-based questionnaire from 14 May 2020 to 1 July 2020 in partnership with several U.S.-based breast cancer advocacy groups. Individuals aged 18 or older were eligible for this study if they: (1) received routine breast cancer screening; OR (2) were undergoing diagnostic evaluation for breast cancer; OR (3) had ever been diagnosed with breast cancer. We used descriptive statistics to understand the extent of cancer care delay and telemedicine adoption and used multivariable logistic regression models to estimate the association of sociodemographic factors with odds of COVID-19-related delays in care and telemedicine use. Results: Of 554 eligible survey participants, 493 provided complete data on demographic and socioeconomic factors and were included in the analysis. Approximately half (n = 248, 50.3%) had a personal history of breast cancer. Overall, 188 (38.1%) participants had experienced any COVID-19-related delay in care including screening, diagnosis, or treatment, and 339 (68.8) reported having at least one virtual appointment during the study period. Compared to other insurance types, participants with Medicaid insurance were 2.58 times more likely to report a COVID-19-related delay in care (OR 2.58, 95% Cl: 1.05, 6.32; p = 0.039). Compared to participants with a household income of less than USD 50,000, those with a household income of USD 150,000 or more were 2.38 (OR 2.38, 95% Cl: 1.09, 5.17; p = 0.029) times more likely to adopt virtual appointments. Self-insured participants were 70% less likely to use virtual appointment compared to those in other insurance categories (OR 0.28, 95% Cl: 0.11, 0.73; p = 0.009). Conclusions: The COVID-19 pandemic has had a significant impact on breast cancer screening, diagnosis, and treatment, and accelerated the delivery of virtual care. Lower-income groups and patients with certain insurance categories such as Medicaid or self-insured could be more likely to experience care delay or less likely to use telemedicine. Careful attention must be paid to vulnerable groups to insure equity in breast cancer-related service utilization and telemedicine access during and beyond the COVID-19 pandemic.

show abstract

“…This discrepancy can be explained by the different settings considered and by the different analytical approaches used in the articles. Nonetheless, the impact of the pandemic on the burden of cancer is still unknown and will probably be fully understood only in the next decades (Malagón et al 2022 ; Englum et al 2022 ). Moreover, the suspension of screening programs in many areas, combined with the reduction of surgical interventions and non-urgent visits, will affect cancer mortality, and increase its burden on societies, in a way which is still difficult to quantify.…”

Section: Discussionmentioning

confidence: 99%

The impact of the SARS-CoV-2 pandemic on cause-specific mortality patterns: a systematic literature review

Sanmarchi

Esposito

Adorno

et al. 2022

J Public Health (Berl.)

View full text Add to dashboard Cite

Background Understanding the effects of the COVID-19 pandemic on cause-specific mortality should be a priority, as this metric allows for a detailed analysis of the true burden of the pandemic. The aim of this systematic literature review is to estimate the impact of the pandemic on different causes of death, providing a quantitative and qualitative analysis of the phenomenon. Methods We searched MEDLINE, Scopus, and ProQuest for studies that reported cause-specific mortality during the COVID-19 pandemic, extracting relevant data. Results A total of 2413 articles were retrieved, and after screening 22 were selected for data extraction. Cause-specific mortality results were reported using different units of measurement. The most frequently analyzed cause of death was cardiovascular diseases (n = 16), followed by cancer (n = 14) and diabetes (n = 11). We reported heterogeneous patterns of cause-specific mortality, except for suicide and road accident. Conclusions Evidence on non-COVID-19 cause-specific deaths is not exhaustive. Reliable scientific evidence is needed by policymakers to make the best decisions in an unprecedented and extremely uncertain historical period. We advocate for the urgent need to find an international consensus to define reliable methodological approaches to establish the true burden of the COVID-19 pandemic on non-COVID-19 mortality.

show abstract

Predicted long‐term impact of COVID‐19 pandemic‐related care delays on cancer mortality in Canada

Cited by 90 publications

References 23 publications

Decrease in the number of patients diagnosed with cancer during the COVID-19 pandemic in Germany

Decrease in the number of patients diagnosed with cancer during the COVID-19 pandemic in Germany

Patient-Reported Experiences of Breast Cancer Screening, Diagnosis, and Treatment Delay, and Telemedicine Adoption during COVID-19

The impact of the SARS-CoV-2 pandemic on cause-specific mortality patterns: a systematic literature review

Contact Info

Product

Resources

About